Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Zentalis Pharmaceuticals announced a proposed underwritten public offering of common stock and pre-funded warrants to fund operations. The company intends to use net proceeds to support clinical trials of azenosertib, regulatory filings, manufacturing and general corporate purposes. TD Cowen, Guggenheim Securities and Oppenheimer & Co.
Key figures
- Option duration days
- 30
- Greenshoe option percent
- 15%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.